Table 2.
Laboratory and clinical parameters of the patients during IVIG therapy
| B19 DNA | IgG anti-PL | |||||||||||||||
| Patient | Sample | ESR (mm/h) | WBC/ml | RBC/ml | Hb (g/dl) | CRP (mg/dl) | CK (U/l) | Arthritis (joints) | Total IgG (mg/dl) | Serum | SF | Anti-CL | Anti-PS | Anti-β2GPI | VAS (doctor) | VAS (parents) |
| 1 | 1 | 5 | 7.96 | 4.21 | 12.0 | neg. | 15 | 2 | 414 | pos. | na | - | - | ++ | 5 | 3 |
| 2 | nd | nd | nd | nd | nd | nd | nd | 1832 | neg. | na | - | - | + | nd | nd | |
| 3 | 5 | 6.88 | 4.25 | 12.3 | neg. | 21 | 0 | 1430 | pos. | na | - | - | - | 1 | 1 | |
| 4 | nd | nd | nd | nd | nd | nd | nd | 2480 | neg. | na | - | - | - | nd | nd | |
| 5 | 9 | 9.58 | 4.36 | 12.3 | neg. | 16 | 0 | 1406 | neg. | na | - | - | (+) | 1 | 1 | |
| 6 | 9 | 7.0 | 4.4 | 12.2 | neg. | 17 | 0 | nd | neg. | na | - | - | - | 1 | 1 | |
| 2 | 1 | 35 | 8.57 | 4.82 | 11.5 | 0.7 | 103 | 4 | 1450 | neg. | na | - | - | + | 4 | 4 |
| 2 | nd | nd | nd | nd | nd | nd | nd | 3040 | neg. | na | - | - | + | n.d | nd | |
| 3 | 37 | 7.47 | 4.43 | 11.3 | 2.6 | 33 | 1 | 468 | neg. | na | - | - | - | 5 | 6 | |
| 3 | nd | nd | nd | nd | nd | nd | nd | 3680 | neg. | na | + | ++ | ++ | nd | nd | |
| 5 | 40 | 6.18 | 4.47 | 11.6 | 1.5 | 30 | 2 | 2020 | pos. | na | - | - | - | 4 | 6 | |
| 6 | 42 | 7.91 | 4.63 | 11.7 | 6.4 | 27 | 2 | nd | neg. | na | - | - | - | 5 | 7 | |
| 3 | 1 | 15 | 6.33 | 4.84 | 13.5 | 0.5 | 20 | 0 | 864 | pos. | na | - | - | - | 5 | 5 |
| 2 | nd | nd | nd | nd | nd | nd | nd | 3600 | pos. | na | - | - | - | nd | nd | |
| 3 | 12 | 6.96 | 4.61 | 13.1 | 0.7 | 25 | 0 | 1604 | pos. | na | - | - | - | 5 | 3 | |
| 4 | nd | nd | nd | nd | nd | nd | nd | 2420 | pos. | pos. | - | ++ | + | nd | nd | |
| 5 | 34 | 9.87 | 4.83 | 13.5 | 0.9 | 25 | 1 | 1734 | neg. | na | - | - | - | 5 | 3 | |
| 6 | 36 | 7.50 | 4.90 | 14.2 | neg. | 20 | 0 | nd | neg. | na | - | - | - | 3 | 2 | |
| 4 | 1 | 30 | 8.99 | 4.32 | 12.5 | 1.5 | 22 | 5 | 1014 | pos. | na | - | - | ++ | 4 | 4 |
| 2 | nd | nd | nd | nd | nd | nd | nd | 2540 | neg. | na | - | ++ | ++ | nd | nd | |
| 3 | 40 | 7.27 | 4.05 | 12.1 | neg. | 32 | 1 | 1724 | pos. | na | - | ++ | ++ | 2 | 2 | |
| 4 | nd | nd | nd | nd | nd | nd | nd | 3420 | neg. | na | - | ++ | ++ | nd | nd | |
| 5 | 21 | 6.45 | 4.07 | 12.6 | neg. | 33 | 1 | 1788 | neg. | na | - | - | - | 1 | 1 | |
| 6 | 10 | 6.50 | 4.35 | 13.3 | neg. | 20 | 0 | nd | neg. | na | - | - | + | 1 | 1 | |
The patients were examined before and after the first treatment cycle (day 1, samples 1; day 5, samples 2), before and after the second treatment cycle (day 1, samples 3; day 5, samples 4), and 1 month (samples 5) and 9 months (samples 6) after the end of the second cycle. In addition to laboratory parameters including the amplification of parvoviral DNA derived from serum or synovial fluid, antiphospholipid antibodies (IgG anti-PL: anti-CL, anti-cardiolipin; anti-PS, anti-phosphatidylserine; anti-β2GPI, anti-β2-glycoprotein I; -, no reaction; +, positive, ++, strongly positive), doctors' and parents' global assessments of overall disease activity were recorded on a visual analogue scale (VAS) ranging from 0 (healthy) to 10 (severely affected). CK, creatine kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hb, haemoglobin; IVIG, high-dose intravenous immunoglobulin; na, not available; nd, not determined; RBC, red blood cells; SF, synovial fluid; WBC, white blood cells.